OncRef

Clinical Trial: NCT06267001

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Status:

TERMINATED

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2026-06-10

Study Overview

Brief Summary

The purpose of this study was to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.

Official Title

A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Conditions

Non-small Cell Lung Cancer (NSCLC)

Intervention / Treatment

  • Drug: Atezolizumab
  • Drug: Tiragolumab
  • Drug: Placebo

Other Study ID Numbers

  • GO45006
  • 2023-506696-10-00
  • 2023

Start Date (Actual)

2024-03-21

Primary Completion Date (Actual)

2025-12-16

Study Completion Date (Actual)

2025-12-16

Enrollment (Actual)

56

Study Type

Interventional

Phase

Phase 3